Rituxan/Mabthera to Maintain the Top Position in Cancer mAbs
2012-03-21 10:05:04 - Despite the entry of biosimilars and stiff competition from other mAbs, Rituxan is likely to maintain its leading position.
As per RNCOS’s new research report entitled “Cancer Monoclonal Antibodies Market to 2015”, cancer represents the fastest growing and one of the most attractive therapeutic segments in the global pharmaceutical market. Among the several drug classes for cancer treatment, antineoplastics mAbs are the leading ones. Key factors, such as fast increase in the number of new cancer cases and the
emergence of innovative technologies led to create a US$ 21 Billion worldwide market for antineoplastic mAbs in 2011. Fuelled by ever-increasing cancer cases globally, the market for the same is portraying an optimistic future outlook, worth17 Million by the end of 2020.
Our research report has found that four drugs currently dominate the global antineoplastics mAbs market, including Roche’s Avastin (bevacizumab), MabThera (rituximab), and Herceptin (trastuzumab); and BMS/Merck’s Erbitux. Rituximab is known as Rituxan in the US, Japan, and Canada, and MabThera in Europe. Drug’s sales are likely to have increased by around 7% and reached a market worth US$ 6.8 Billion by the end of 2011. Though in the coming future, Rituxan will face a threat from the entry of bio-similar versions, it is likely to maintain its dominance as the market-leading agent and is anticipated to advance at a CAGR of 5.4% during 2012-2015.
The report investigates and analyzes all the key developments of cancer mAbs’ market throughout the world. It also identifies the possible growth areas in terms of pipeline products and provides an in-depth analysis on the leading drugs under development with reference to their manufacturers and other key details. It also covers an exhaustive research on the country-level cancer mAbs market and offers a broad overview of the current developments.
The report, which is an outcome of prudent analysis and extensive research on the antineoplastic mAbs market, is spread in over 100 pages. It also provides future forecasts for the overall industry and key sections/areas on the basis of past trends, challenges, opportunities for expansion and economic and judgmental analysis. Further, the report illustrates about the approved mAbs, along with their recent industry developments to provide a balanced outlook on the potentials of the growing market.
For FREE SAMPLE of this report visit: www.rncos.com/Report/IM375.htm
Some of our Related Reports are:
- Indian Healthcare - New Avenues for Growth
- Insulin Delivery Systems Market Forecast to 2014
- Global Genetic Testing Market Analysis ( www.rncos.com/Report/IM352.htm
- US Diagnostic Market Outlook 2014 ( www.rncos.com/Report/IM298.htm
- Global In Vitro Diagnostic Market Analysis ( www.rncos.com/Report/IM103.htm
Check Related REPORTS on: www.rncos.com/Healthcare_Industry.htm
RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.